Cybin (HELP) FDA Approvals $6.83 -0.37 (-5.13%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Cybin's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Cybin (HELP). Over the past two years, Cybin has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as HLP003. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. HLP003 FDA Regulatory Timeline and Events HLP003 is a drug developed by Cybin for the following indication: adjunctive treatment of major depressive disorder ("MDD"). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Top-line results - November 16,2026Top-Line Results Phase 3Drug: HLP003Announced Date: November 16, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma Inc. announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder ("MDD").AI SummaryHelus Pharma announced positive topline results from APPROACH, a Phase 3 trial of HLP003 (deuterated psilocin) alongside existing antidepressants in adults with moderate-to-severe major depressive disorder. The 222-participant study found rapid and lasting improvement on a depression rating scale. By Day 2, scores improved 5.0 points more with HLP003 than with placebo (p=0.0013). At Week 6, the difference was 7.6 points (p<0.0001), meeting the primary endpoint. At Week 12, the benefit remained 7.0 points (p<0.0001). Response and remission rates were also higher with HLP003, with significant differences seen from Day 2 onward. At Week 6, 56.3% of participants responded, versus 28.2% on placebo; 50.9% reached remission, compared with 18.2%. HLP003 was generally well tolerated. Most side effects were mild to moderate, brief, and occurred on dosing day. Three serious events were considered treatment-related, and the company reported no new safety signals. A second Phase 3 study is ongoing.Read AnnouncementProvided Update - November 15,2026Provided Update Drug: HLP003Announced Date: November 15, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma Inc. announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder ("MDD").AI SummaryHelus Pharma Inc. will host a webcast on November 16, 2026, at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study. The study is evaluating HLP003, the company’s investigational drug candidate, as an add-on treatment for major depressive disorder (MDD). The announcement does not include the study results; they will be shared during the webcast. Viewers can join through the webcast link or the Events & Presentations page on Helus Pharma’s website. A recording will be posted there after the presentation. Helus Pharma is a clinical-stage company developing serotonergic agonists, which are designed to act on serotonin pathways. The company says its drug candidates are being developed to address unmet needs in mental health. HLP003 is in Phase 3 development for MDD, while another candidate, HLP004, is being studied in Phase 2 for generalized anxiety disorder. The company cautions that its proposed products have not been proven to diagnose, treat, cure, or prevent any disease.Read AnnouncementPresentation - September 21,2026Presentation Drug: HLP003Announced Date: September 21, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.AI SummaryHelus Pharma presented four posters on HLP003, an investigational oral deuterated psilocin analog being studied as an add-on treatment for major depressive disorder (MDD), at Psych Congress 2026. The meeting took place September 15–19 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Three posters reported further analyses of the company’s completed Phase 1/2a study. They examined changes in individual depression symptoms and anhedonia, how participants experienced the treatment, and expanded safety findings. The company also presented 12-month efficacy results from the study. A fourth, trial-in-progress poster outlined PARADIGM, Helus Pharma’s ongoing Phase 3 program evaluating HLP003’s efficacy and safety as an adjunctive MDD treatment. The presentations add detail on HLP003’s clinical profile and the design of its late-stage development program; the treatment remains investigational.Read AnnouncementEnrollment Update - July 21,2026Enrollment Update Phase 3Drug: HLP003Announced Date: July 21, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder ("MDD").AI SummaryHelus Pharma said it has finished enrolling patients in APPROACH, the first pivotal Phase 3 study in its PARADIGM program for HLP003 in adults with major depressive disorder. The study includes people with moderate to severe MDD who still have symptoms despite taking a stable antidepressant. Reaching full enrollment is an important step toward the company’s planned topline data readout in the fourth quarter of 2026. The broader PARADIGM program is also moving forward. Enrollment is still ongoing in EMBRACE, the second pivotal Phase 3 study. Some participants from APPROACH and EMBRACE may later move into EXTEND, a long-term study designed to gather more safety, durability, and possible redosing data. Helus Pharma said the program is built to support clear and reliable results, with placebo control, safety monitoring, and longer-term follow-up.Read AnnouncementEnrollment Update - June 24,2026Enrollment Update Phase 3Drug: HLP003Announced Date: June 24, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma™ nnounced that enrollment in the APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment.AI SummaryHelus Pharma said enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder is moving ahead as planned and is now more than 86% complete. The company said this study is testing both the safety and effectiveness of HLP003 as an add-on treatment for patients with MDD, and it is part of a larger Phase 3 program. Helus also pointed to earlier Phase 2 results that showed strong and lasting benefits. In those data, patients had about a 23-point drop in MADRS scores after 12 months, following two 16 mg doses given three weeks apart. Response and remission rates were 75% at week 18, then improved to 100% and 71% by 12 months. The company said it remains on track to report topline Phase 3 data in Q4 2026.Read Announcement Cybin FDA Events - Frequently Asked Questions Has Cybin received FDA approval? As of now, Cybin (HELP) has not received any FDA approvals for its therapy in the last two years. What drugs has Cybin submitted to the FDA? In the past two years, Cybin (HELP) has reported FDA regulatory activity for HLP003. What is the most recent FDA event for Cybin? The most recent FDA-related event for Cybin occurred on November 16, 2026, involving HLP003. The update was categorized as "Top-line results," with the company reporting: "Helus Pharma Inc. announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder ("MDD")." What conditions do Cybin's current drugs treat? Currently, Cybin has one therapy (HLP003) targeting the following condition: adjunctive treatment of major depressive disorder ("MDD"). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Actuate Therapeutics FDA EventsEnlivex Therapeutics FDA EventsImmuneering FDA EventsInnate Pharma FDA EventsNovabridge Biosciences FDA EventsOptimi Health FDA EventsRecursion Pharmaceuticals FDA EventsSummit Therapeutics FDA EventsACADIA Pharmaceuticals FDA EventsBiogen FDA EventsEikon Therapeutics FDA EventsGain Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies HUTCHMED FDA Events MBX Biosciences FDA Events Trevi Therapeutics FDA Events Harmony Biosciences FDA Events Eton Pharmaceuticals FDA Events ANI Pharmaceuticals FDA Events Rapport Therapeutics FDA Events Ocular Therapeutix FDA Events Pacira BioSciences FDA Events LB Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:HELP last updated on 11/16/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Top-line results - November 16,2026Top-Line Results Phase 3Drug: HLP003Announced Date: November 16, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma Inc. announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder ("MDD").AI SummaryHelus Pharma announced positive topline results from APPROACH, a Phase 3 trial of HLP003 (deuterated psilocin) alongside existing antidepressants in adults with moderate-to-severe major depressive disorder. The 222-participant study found rapid and lasting improvement on a depression rating scale. By Day 2, scores improved 5.0 points more with HLP003 than with placebo (p=0.0013). At Week 6, the difference was 7.6 points (p<0.0001), meeting the primary endpoint. At Week 12, the benefit remained 7.0 points (p<0.0001). Response and remission rates were also higher with HLP003, with significant differences seen from Day 2 onward. At Week 6, 56.3% of participants responded, versus 28.2% on placebo; 50.9% reached remission, compared with 18.2%. HLP003 was generally well tolerated. Most side effects were mild to moderate, brief, and occurred on dosing day. Three serious events were considered treatment-related, and the company reported no new safety signals. A second Phase 3 study is ongoing.Read Announcement
Provided Update - November 15,2026Provided Update Drug: HLP003Announced Date: November 15, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma Inc. announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder ("MDD").AI SummaryHelus Pharma Inc. will host a webcast on November 16, 2026, at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study. The study is evaluating HLP003, the company’s investigational drug candidate, as an add-on treatment for major depressive disorder (MDD). The announcement does not include the study results; they will be shared during the webcast. Viewers can join through the webcast link or the Events & Presentations page on Helus Pharma’s website. A recording will be posted there after the presentation. Helus Pharma is a clinical-stage company developing serotonergic agonists, which are designed to act on serotonin pathways. The company says its drug candidates are being developed to address unmet needs in mental health. HLP003 is in Phase 3 development for MDD, while another candidate, HLP004, is being studied in Phase 2 for generalized anxiety disorder. The company cautions that its proposed products have not been proven to diagnose, treat, cure, or prevent any disease.Read Announcement
Presentation - September 21,2026Presentation Drug: HLP003Announced Date: September 21, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.AI SummaryHelus Pharma presented four posters on HLP003, an investigational oral deuterated psilocin analog being studied as an add-on treatment for major depressive disorder (MDD), at Psych Congress 2026. The meeting took place September 15–19 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Three posters reported further analyses of the company’s completed Phase 1/2a study. They examined changes in individual depression symptoms and anhedonia, how participants experienced the treatment, and expanded safety findings. The company also presented 12-month efficacy results from the study. A fourth, trial-in-progress poster outlined PARADIGM, Helus Pharma’s ongoing Phase 3 program evaluating HLP003’s efficacy and safety as an adjunctive MDD treatment. The presentations add detail on HLP003’s clinical profile and the design of its late-stage development program; the treatment remains investigational.Read Announcement
Enrollment Update - July 21,2026Enrollment Update Phase 3Drug: HLP003Announced Date: July 21, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder ("MDD").AI SummaryHelus Pharma said it has finished enrolling patients in APPROACH, the first pivotal Phase 3 study in its PARADIGM program for HLP003 in adults with major depressive disorder. The study includes people with moderate to severe MDD who still have symptoms despite taking a stable antidepressant. Reaching full enrollment is an important step toward the company’s planned topline data readout in the fourth quarter of 2026. The broader PARADIGM program is also moving forward. Enrollment is still ongoing in EMBRACE, the second pivotal Phase 3 study. Some participants from APPROACH and EMBRACE may later move into EXTEND, a long-term study designed to gather more safety, durability, and possible redosing data. Helus Pharma said the program is built to support clear and reliable results, with placebo control, safety monitoring, and longer-term follow-up.Read Announcement
Enrollment Update - June 24,2026Enrollment Update Phase 3Drug: HLP003Announced Date: June 24, 2026Indication: adjunctive treatment of major depressive disorder ("MDD")AnnouncementHelus Pharma™ nnounced that enrollment in the APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment.AI SummaryHelus Pharma said enrollment in its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder is moving ahead as planned and is now more than 86% complete. The company said this study is testing both the safety and effectiveness of HLP003 as an add-on treatment for patients with MDD, and it is part of a larger Phase 3 program. Helus also pointed to earlier Phase 2 results that showed strong and lasting benefits. In those data, patients had about a 23-point drop in MADRS scores after 12 months, following two 16 mg doses given three weeks apart. Response and remission rates were 75% at week 18, then improved to 100% and 71% by 12 months. The company said it remains on track to report topline Phase 3 data in Q4 2026.Read Announcement